Opthea Limited Sponsored ADR (OPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on the stock and has a $12.00 price target.
Matthew Caufield has given his Buy rating due to a combination of factors surrounding Opthea Limited’s promising developments in their treatment for wet age-related macular degeneration (AMD). The company is on the brink of releasing significant data from their Phase 3 COAST trial in early Q2 2025, which evaluates the efficacy of sozinibercept in combination with aflibercept. This trial, along with the anticipated results from the Phase 3 ShORe trial in mid-2025, builds on strong Phase 2b outcomes, suggesting that sozinibercept could offer superior vision improvements when used alongside standard anti-VEGF-A therapies.
Caufield highlights the potential of sozinibercept as a novel VEGF-C/D trap, which may provide broader inhibition of VEGFR receptors, thus enhancing patient vision outcomes. The Phase 2b trial demonstrated statistically significant visual acuity gains, which bolsters confidence in the upcoming Phase 3 results. Additionally, the flexibility in treatment intervals offered by sozinibercept could allow for extended injection schedules, providing retinal specialists with more options for patient care. These factors collectively underpin Caufield’s optimistic outlook and Buy rating for Opthea Limited’s stock, with a price target of $12.
Caufield covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Opus Genetics, and Opthea Limited Sponsored ADR. According to TipRanks, Caufield has an average return of -12.6% and a 28.99% success rate on recommended stocks.
In another report released on February 18, JonesTrading also reiterated a Buy rating on the stock with a $13.00 price target.